Clinical Trial Update: Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload [Phase 2]

View source ↗

Summary

Phase 2 safety and pharmacodynamic study of an oral iron chelator given for 6 months in patients with transfusional iron overload and beta-thalassemia completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Transfusional Iron Overload

Drugs mentioned

• oral iron chelator

Snippet

Sponsor: Shire | Conditions: Transfusional Iron Overload, Beta-thalassemia | Phase 2 | Status: COMPLETED | Results posted: 2015-06-03